Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

Inclusion Criteria:

• High pretest probability of CAD based on the ACC/AHA guidelines for relative risk, orpast medical h/o CAD

Exclusion Criteria:

• Ingestion of a caffeinated or methylxanthine food substance (e.g. chocolate, cocoa)within 24 hours before receiving apadenoson or adenosine

• Treatment with dipyridamole within 24 hours, or theophylline, aminophylline, orpentoxifylline within 72 hours (or 4 half-lives, whichever is longer) prior toreceiving apadenoson or adenosine

• Acute MI, new onset of ischemia or PCI within 30 days prior to SPECT-MPI at eitherPeriod 1 or Period 2; or CABG within 90 days prior to SPECT-MPI at either Period 1 orPeriod 2

• Active severe asthma or severe chronic obstructive pulmonary disease (COPD) which, inthe Investigator's opinion, places the subject at risk for severe bronchoconstriction

• History or evidence of clinically significant cardiac condition and rhythm disorder,in the absence of a functioning permanently implanted pacemaker

• Hemodynamically significant valvular disease, outflow tract obstruction, oruncontrolled severe hypertension

• Current significant medical, surgical, psychiatric, or other illness or pathology thatcould potentiate any adverse pharmacological event associated with an investigationaldrug

• Subject with past medical history of hepatitis B or C, or recent hepatitis A

• Pretreatment hypotension (systolic BP < 90 mm Hg) or tachycardia (HR > 100 bpm)

• Known history of cerebral vascular accident or suspected transient ischemic attackwithin 30 days prior to signed informed consent